{"database": "openregs", "table": "documents", "is_view": false, "human_description_en": "where docket_id = \"FDA-2022-N-2390\" and posted_year = 2023 sorted by posted_date descending", "rows": [["FDA-2022-N-2390-0030", "FDA", "FDA-2022-N-2390", "Response from Vanda Pharmaceuticals Inc. Response to FDA CDER", "Other", "Response(s)", "2023-10-19T04:00:00Z", 2023, 10, "2023-10-19T04:00:00Z", null, "2023-10-19T19:33:28Z", null, 0, 0, "090000648610f7c8"], ["FDA-2022-N-2390-0029", "FDA", "FDA-2022-N-2390", "Letter from McDermott Will & Emery on behalf of Vanda Pharmaceuticals Inc.", "Other", "Letter(s)", "2023-09-29T04:00:00Z", 2023, 9, "2023-09-29T04:00:00Z", null, "2023-09-29T17:42:03Z", null, 0, 0, "090000648600f7cf"], ["FDA-2022-N-2390-0028", "FDA", "FDA-2022-N-2390", "Letter from McDermott Will & Emery on behalf of Vanda Pharmaceuticals, Inc to FDA CDER", "Other", "Letter(s)", "2023-09-19T04:00:00Z", 2023, 9, "2023-09-19T04:00:00Z", null, "2023-09-19T18:30:32Z", null, 0, 0, "0900006485fd20d7"], ["FDA-2022-N-2390-0026", "FDA", "FDA-2022-N-2390", "Participation of Chief Counsel Mark Raza in re: Proposal to Refuse to Approve a New Drug Application Supplement for Hetlioz (Tasimelteon); Opportunity for a Hearing", "Other", "Memo", "2023-08-30T04:00:00Z", 2023, 8, "2023-08-30T04:00:00Z", null, "2023-08-30T19:13:12Z", null, 0, 0, "0900006485f14bbc"], ["FDA-2022-N-2390-0027", "FDA", "FDA-2022-N-2390", "Mark Raza\u2019s Participation in Vanda Pharmaceuticals", "Other", "Memo", "2023-08-30T04:00:00Z", 2023, 8, "2023-08-30T04:00:00Z", null, "2023-08-30T19:13:23Z", null, 0, 0, "0900006485f14bc0"], ["FDA-2022-N-2390-0025", "FDA", "FDA-2022-N-2390", "Vanda's Response to CDER's Proposed Order", "Other", "Response(s)", "2023-08-17T04:00:00Z", 2023, 8, "2023-08-17T04:00:00Z", null, "2023-08-17T18:27:06Z", null, 0, 0, "0900006485e77eab"], ["FDA-2022-N-2390-0024", "FDA", "FDA-2022-N-2390", "Vanda's Response to CDER's Proposed Order", "Other", "Response(s)", "2023-08-17T04:00:00Z", 2023, 8, "2023-08-17T04:00:00Z", null, "2023-08-17T18:24:44Z", null, 0, 0, "0900006485e60684"], ["FDA-2022-N-2390-0020", "FDA", "FDA-2022-N-2390", "Cover Memorandum to Vanda RE: Proposal To Refuse To Approve a New Drug Application Supplement for HETLIOZ (Tasimelteon); Opportunity for a Hearing", "Supporting & Related Material", "Background Material", "2023-06-22T04:00:00Z", 2023, 6, null, null, "2023-06-22T14:42:06Z", null, 0, 0, "0900006485bb01e9"], ["FDA-2022-N-2390-0022", "FDA", "FDA-2022-N-2390", "Proposed Order RE: Proposal To Refuse To Approve a New Drug Application Supplement for HETLIOZ (Tasimelteon); Opportunity for a Hearing", "Supporting & Related Material", "Background Material", "2023-06-22T04:00:00Z", 2023, 6, null, null, "2023-06-22T14:42:13Z", null, 0, 0, "0900006485bb0f98"], ["FDA-2022-N-2390-0023", "FDA", "FDA-2022-N-2390", "ICSD-3 3rd edition (2014) Insomnia RE: Proposal To Refuse To Approve a New Drug Application Supplement for HETLIOZ (Tasimelteon); Opportunity for a Hearing", "Supporting & Related Material", "Background Material", "2023-06-22T04:00:00Z", 2023, 6, null, null, "2023-06-22T17:08:07Z", null, 0, 0, "0900006485bb0f99"], ["FDA-2022-N-2390-0021", "FDA", "FDA-2022-N-2390", "Cover Memorandum to Commissioner RE: Proposal To Refuse To Approve a New Drug Application Supplement for HETLIOZ (Tasimelteon); Opportunity for a Hearing", "Supporting & Related Material", "Background Material", "2023-06-22T04:00:00Z", 2023, 6, null, null, "2023-06-22T14:42:10Z", null, 0, 0, "0900006485bb01ea"], ["FDA-2022-N-2390-0019", "FDA", "FDA-2022-N-2390", "Vanda Scheduling Order", "Other", "Order", "2023-05-25T04:00:00Z", 2023, 5, "2023-05-25T04:00:00Z", null, "2023-05-25T17:26:03Z", null, 0, 0, "0900006485a613f6"], ["FDA-2022-N-2390-0018", "FDA", "FDA-2022-N-2390", "Letter from McDermott Will & Emery on behalf of Vanda Pharmaceuticals, Inc to FDA CDER", "Other", "Letter(s)", "2023-04-12T04:00:00Z", 2023, 4, "2023-04-12T04:00:00Z", null, "2023-04-12T17:21:59Z", null, 0, 0, "090000648593604b"], ["FDA-2022-N-2390-0017", "FDA", "FDA-2022-N-2390", "Letter to Matthew Warren from FDA CDER", "Other", "Letter(s)", "2023-02-21T05:00:00Z", 2023, 2, "2023-02-21T05:00:00Z", null, "2023-02-21T18:53:15Z", null, 0, 0, "09000064856def37"], ["FDA-2022-N-2390-0016", "FDA", "FDA-2022-N-2390", "Vanda Submission Ex 032 (audio file)", "Other", "Record of Meeting/Phone Conversation", "2023-01-20T05:00:00Z", 2023, 1, "2023-01-20T05:00:00Z", null, "2023-01-20T19:12:20Z", null, 0, 0, "09000064855fce7d"], ["FDA-2022-N-2390-0014", "FDA", "FDA-2022-N-2390", "Letter from Vanda Pharmaceuticals, Inc to FDA CDER and FDA DMS", "Other", "Letter(s)", "2023-01-10T05:00:00Z", 2023, 1, "2023-01-10T05:00:00Z", null, "2023-01-10T18:35:16Z", null, 0, 0, "09000064855d315f"], ["FDA-2022-N-2390-0015", "FDA", "FDA-2022-N-2390", "Letter to Vanda Pharmaceuticals, Inc and FDA CDER", "Other", "Letter(s)", "2023-01-10T05:00:00Z", 2023, 1, "2023-01-10T05:00:00Z", null, "2023-01-10T18:35:27Z", null, 0, 0, "09000064855d315d"]], "truncated": false, "filtered_table_rows_count": 17, "expanded_columns": [], "expandable_columns": [[{"column": "docket_id", "other_table": "dockets", "other_column": "id"}, "title"]], "columns": ["id", "agency_id", "docket_id", "title", "document_type", "subtype", "posted_date", "posted_year", "posted_month", "comment_start_date", "comment_end_date", "last_modified", "fr_doc_num", "open_for_comment", "withdrawn", "object_id"], "primary_keys": ["id"], "units": {}, "query": {"sql": "select id, agency_id, docket_id, title, document_type, subtype, posted_date, posted_year, posted_month, comment_start_date, comment_end_date, last_modified, fr_doc_num, open_for_comment, withdrawn, object_id from documents where \"docket_id\" = :p0 and \"posted_year\" = :p1 order by posted_date desc limit 101", "params": {"p0": "FDA-2022-N-2390", "p1": "2023"}}, "facet_results": {"agency_id": {"name": "agency_id", "type": "column", "hideable": false, "toggle_url": "/openregs/documents.json?docket_id=FDA-2022-N-2390&posted_year=2023", "results": [{"value": "FDA", "label": "FDA", "count": 17, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2022-N-2390&posted_year=2023&agency_id=FDA", "selected": false}], "truncated": false}, "document_type": {"name": "document_type", "type": "column", "hideable": false, "toggle_url": "/openregs/documents.json?docket_id=FDA-2022-N-2390&posted_year=2023", "results": [{"value": "Other", "label": "Other", "count": 13, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2022-N-2390&posted_year=2023&document_type=Other", "selected": false}, {"value": "Supporting & Related Material", "label": "Supporting & Related Material", "count": 4, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2022-N-2390&posted_year=2023&document_type=Supporting+%26+Related+Material", "selected": false}], "truncated": false}, "posted_year": {"name": "posted_year", "type": "column", "hideable": false, "toggle_url": "/openregs/documents.json?docket_id=FDA-2022-N-2390&posted_year=2023", "results": [{"value": 2023, "label": 2023, "count": 17, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2022-N-2390", "selected": true}], "truncated": false}}, "suggested_facets": [{"name": "title", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2022-N-2390&posted_year=2023&_facet=title"}, {"name": "subtype", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2022-N-2390&posted_year=2023&_facet=subtype"}, {"name": "posted_date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2022-N-2390&posted_year=2023&_facet=posted_date"}, {"name": "posted_month", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2022-N-2390&posted_year=2023&_facet=posted_month"}, {"name": "comment_start_date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2022-N-2390&posted_year=2023&_facet=comment_start_date"}, {"name": "posted_date", "type": "date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2022-N-2390&posted_year=2023&_facet_date=posted_date"}, {"name": "comment_start_date", "type": "date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2022-N-2390&posted_year=2023&_facet_date=comment_start_date"}, {"name": "last_modified", "type": "date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2022-N-2390&posted_year=2023&_facet_date=last_modified"}], "next": null, "next_url": null, "private": false, "allow_execute_sql": true, "query_ms": 1509.355193004012, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}